4.1 Article

The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients. Part II: Therapy and Prevention

期刊

UROLOGIA INTERNATIONALIS
卷 100, 期 3, 页码 271-278

出版社

KARGER
DOI: 10.1159/000487645

关键词

Urinary tract infection; Cystitis; Pyelonephritis; Therapy; Systematic review; Clinical guideline

资金

  1. Leo Pharma
  2. Astellas
  3. Monika Kutzner Stiftung
  4. Pfizer
  5. Bionorica
  6. Daiichi Sanchyo
  7. MerLion
  8. OM-Pharma
  9. Rosen Pharma
  10. Zambon
  11. Basilea
  12. Enteris
  13. Helperby
  14. Rosen-Pharma
  15. Akademie der Deutschen Urologen
  16. CGC Cramer
  17. Fischerappelt
  18. Fresenius
  19. Gilead
  20. Infectopharm
  21. MDS
  22. MedConcept
  23. MIM-Verlag
  24. Omega/Abtei
  25. Pfleger
  26. Springer-Verlag
  27. Strathmann Thieme-Verlag
  28. Uromed
  29. Achaogen
  30. AstraZeneca
  31. Cubist
  32. Galenus
  33. MSD
  34. Pierre Fabre
  35. Pierelle Research
  36. Calixa
  37. DFG
  38. Europ

向作者/读者索取更多资源

Background: We aimed to update the 2010 evidence- and consensus-based national clinical guideline on the diagnosis and management of uncomplicated urinary tract infections (UTIs) in adult patients. Results are published in 2 parts. Part 1 covers methods, the definition of patient groups, and diagnostics. This second publication focuses on treatment of acute episodes of cystitis and pyelonephritis as well as on prophylaxis of recurrent UTIs. Materials and Methods: An interdisciplinary group consisting of 17 representatives of 12 medical societies and a patient representative was formed. Systematic literature searches were conducted in MEDLINE, EMBASE, and the Cochrane Library to identify literature published in 2010-2015. Results: For the treatment of acute uncomplicated cystitis (AUC), fosfomycin-trometamol, nitrofurantoin, nitroxoline, pivmecillinam, and trimethoprim (depending on the local rate of resistance) are all equally recommended. Cotrimoxazole, fluoroquinolones, and cephalosporins are not recommended as antibiotics of first choice, for concern of an unfavorable impact on the microbiome. Mild to moderate uncomplicated pyelonephritis should be treated with oral cefpodoxime, ceftibuten, ciprofloxacin, or levofloxacin. For AUC with mild to moderate symptoms, instead of antibiotics symptomatic treatment alone may be considered depending on patient preference after discussing adverse events and outcomes. Primarily non-antibiotic options are recommended for prophylaxis of recurrent urinary tract infection. Conclusion: In accordance with the global antibiotic stewardship initiative and considering new insights in scientific research, we updated our German clinical UTI guideline to promote a responsible antibiotic use and to give clear hands-on recommendations for the diagnosis and management of UTIs in adults in Germany for healthcare providers and patients. (c) 2018 S. Karger AG, Basel.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据